

3rd European Symposium in Hypoparathyroidism

A Takeda-sponsored standalone meeting

Date:	8–9 November 2019
Time:	Day 1 08:30–17:50 Day 2 08:30–13:25
Location:	Radisson Blu Park Hotel Leof. Alexandras 10, Athens 106 82, Greece
Meeting title:	Clinical aspects for diagnosing and achieving disease control in chronic hypoparathyroidism
Meeting Co-Chairs	Professor John Bilezikian, USA Dr Andromachi Vryonidou-Bompota, Greece Professor Lars Rejnmark, Denmark

Overarching meeting objectives

1. To summarise the importance of parathyroid hormone (PTH) in mineral homeostasis
2. To understand the characteristics of not adequately controlled patients with hypoparathyroidism (hypoPT), and the importance of achieving good biochemical control and avoiding disease-associated complications and comorbidities
3. To review current treatment goals and guidelines for hypoPT and discuss the importance of translating these guidelines to clinical practice to achieve good disease control in patients with hypoPT
4. To explore how new evidence can help facilitate the understanding of hypoPT and its management, and how it will help to improve patient outcomes

This event is only open to healthcare professionals who register to attend. This meeting is initiated and funded by Takeda Global Medical Affairs. Presenters are paid an honorarium by Takeda for their participation in and consultation to this programme.

Copyright © 2019 Takeda Pharmaceutical Company Limited. All rights reserved

3rd European Symposium in Hypoparathyroidism

A Takeda-sponsored standalone meeting

Agenda | Day 1

08:00–08:30	Welcome refreshments
08:30–08:40	Welcome and introduction <i>Meeting Co-Chairs: Professor John Bilezikian, USA and Dr Andromachi Vryonidou-Bompota, Greece</i>
Session 1: The biology of mineral homeostasis, imbalance and complications in hypoparathyroidism	
Chair: Professor Lars Rejnmark, Denmark Objectives: <ul style="list-style-type: none">• To summarise the importance of PTH in mineral homeostasis• To review the comorbidities associated with hypoPT with a focus on biochemical, renal, bone and neurocognitive symptoms• To discuss the impact of hypoPT comorbidities on patients' quality of life (QoL)• To explore the diagnostic challenges of iatrogenic hypoPT as well as the diagnosis and management in patients with genetic and autoimmune diseases	
08:40–09:10	The clinical presentation of patients with hypoparathyroidism and the importance of the parathyroid hormone in mineral homeostasis <i>(Opening keynote presentation)</i> <i>Speaker: Dr Maria Yavropoulou, Greece</i>
09:10–09:30	The importance of biochemical control in hypoparathyroidism <i>(Plenary presentation)</i> <i>Speaker: Professor Lars Rejnmark, Denmark</i>
09:30–09:50	The importance of kidneys in mineral homeostasis <i>(Plenary presentation)</i> <i>Speaker: Professor Bill Fraser, UK</i>
09:50–10:00	Coffee break
10:00–11:40	Challenges in diagnosing hypoparathyroidism in particular patient groups <i>(Parallel workshop session: each workshop will have a duration of 45 minutes, with a 10-minute break in between)</i> Workshop 1 Non-surgical hypoparathyroidism: Unique challenges in patients with hypoparathyroidism caused by genetic mutations <i>Moderator: Professor Olle Kämpe, Sweden</i> Workshop 2 Post-surgical hypoparathyroidism: Potential diagnostic and follow-up challenges and risk and prediction factors leading to chronic disease

This event is only open to healthcare professionals who register to attend. This meeting is initiated and funded by Takeda Global Medical Affairs. Presenters are paid an honorarium by Takeda for their participation in and consultation to this programme.

Copyright © 2019 Takeda Pharmaceutical Company Limited. All rights reserved

3rd European Symposium in Hypoparathyroidism

A Takeda-sponsored standalone meeting

	<i>Moderators: Dr Tom Kurzawinski, UK and Professor Volker Fendrich, Germany</i>
11:40–11:50	Coffee break
11:50–12:10	The role of bone in normal mineral homeostasis and potential metabolic effects in hypoparathyroidism <i>(Plenary presentation)</i> <i>Speaker: Professor John Bilezikian, USA</i>
12:10–12:30	Potential tools to help understand and evaluate cognitive symptoms in hypoparathyroidism and their pertinence to quality of life measurements <i>(Plenary presentation)</i> <i>Speaker: Professor Leif Østergaard, Denmark</i>
12:30–13:15	Abnormal mineral homeostasis in hypoparathyroidism: A roundtable discussion Suggested topics for discussion include: <ul style="list-style-type: none"> • How to diagnose hypoPT difficult cases • The role of the kidneys, bone and appropriate biochemical control in associated complications and comorbidities <i>Moderator: Professor Bart Clarke, USA</i> <i>Faculty panel:</i> <i>Dr Maria Yavropoulou, Greece</i> <i>Professor Lars Rejnmark, Denmark</i> <i>Professor Bill Fraser, UK</i> <i>Professor Olle Kämpe, Sweden</i> <i>Dr Tom Kurzawinski, UK</i> <i>Professor Volker Fendrich, Germany</i> <i>Professor John Bilezikian, USA</i> <i>Professor Leif Østergaard, Denmark</i> <i>Dr Andromachi Vryonidou-Bompota, Greece</i>
13:15–14:00	Lunch
Session 2: The not adequately controlled hypoparathyroidism patient Chair: Professor Neil Gittoes, UK Objectives: <ul style="list-style-type: none"> • To review current treatment goals and guidelines for hypoPT, with a focus on reaching an expert consensus for the management of not adequately controlled patients with hypoPT • To discuss the management of patients with not adequately controlled hypoPT who present with an impaired QoL and biochemical, renal and multisystem comorbidities 	
14:00–14:20	When is the hypoparathyroidism patient not well controlled? Guidance and clinical experience <i>(Plenary presentation)</i> <i>Speaker: Professor Maria Luisa Brandi, Italy</i>
14:20–16:55	Managing patients with hypoparathyroidism who present with impaired quality of life, and biochemical, renal and multisystem comorbidities

This event is only open to healthcare professionals who register to attend. This meeting is initiated and funded by Takeda Global Medical Affairs. Presenters are paid an honorarium by Takeda for their participation in and consultation to this programme.

Copyright © 2019 Takeda Pharmaceutical Company Limited. All rights reserved

3rd European Symposium in Hypoparathyroidism

A Takeda-sponsored standalone meeting

	<p><i>(Parallel workshop session: each workshop will have a duration of 45 minutes, with a 10-minute break in between)</i></p> <p>Workshop 3 Patient cases with compromised biochemical parameters Suggested topics for discussion:</p> <ul style="list-style-type: none"> • Abnormal serum calcium • Increased 24-hour urinary calcium excretion/renal comorbidities <p><i>Moderators: Professor Karin Amrein, Austria and Professor Lars Rejnmark, Denmark</i></p> <p>Workshop 4 Patient cases with multisystem comorbidities: Is there a common thread? <i>Moderators: Dr Sigridur Björnsdottir, Sweden and Professor Salvatore Minisola, Italy</i></p> <p>Workshop 5 Patient cases with persistent neurocognitive symptoms and impaired quality of life <i>Moderators: Dr Tanja Sikjaer, Denmark and Professor Heide Siggelkow, Germany</i></p>
16:55–17:10	Coffee break
17:00–17:45	<p>Recognising patients with not adequately controlled hypoparathyroidism: A roundtable discussion Suggested topics for discussion include:</p> <ul style="list-style-type: none"> • What are the parameters that should be considered to effectively identify patients with hypoPT • Translating guidelines to clinical practice • Can we predict and/or prevent hypoPT-associated comorbidities in newly diagnosed patients? <p><i>Moderator: Professor Neil Gittoes, USA</i> <i>Faculty panel:</i> <i>Professor Maria Luisa Brandi, Italy</i> <i>Professor Karin Amrein, Austria</i> <i>Professor Lars Rejnmark, Denmark</i> <i>Dr Sigridur Björnsdottir, Sweden</i> <i>Professor Salvatore Minisola, Italy</i> <i>Dr Tanja Sikjaer, Denmark</i> <i>Professor Heide Siggelkow, Germany</i></p>
17:45–17:50	<p>Day 1 summary and close <i>Meeting Chair: Professor John Bilezikian UK</i></p>

This event is only open to healthcare professionals who register to attend. This meeting is initiated and funded by Takeda Global Medical Affairs. Presenters are paid an honorarium by Takeda for their participation in and consultation to this programme.

Copyright © 2019 Takeda Pharmaceutical Company Limited. All rights reserved

3rd European Symposium in Hypoparathyroidism

A Takeda-sponsored standalone meeting

Agenda | Day 2

08:00–08:30	Welcome refreshments
08:30–08:40	Day 2 welcome and introduction <i>Meeting Chair: Professor Lars Rejnmark, Denmark</i>
Session 3: Management of hypoparathyroidism <i>Chair: Professor John Bilezikian, USA</i> Objectives: <ul style="list-style-type: none">• To discuss how clinical practice adheres to published guidance for the management of hypoPT• To summarise the use of PTH as a treatment option and practical aspects of its use in clinical practice• To explore how new evidence can help facilitate the understanding of hypoPT and its management	
08:40–09:10	Current guidelines and anticipated updates: Key learnings and challenges from clinical practice <i>(Keynote presentation)</i> <i>Speaker: Professor Jens Bollerslev, Norway</i>
09:10–09:30	Parathyroid hormone as a direct management option in patients with chronic hypoparathyroidism <i>(Plenary presentation)</i> <i>Speaker: Professor Bart Clarke, USA</i>
09:30–09:40	Coffee break
09:40–11:15	The management and monitoring of patients with hypoparathyroidism <i>(Parallel workshop session: each workshop will have a duration of 45 minutes, with a 10-minute break in between)</i> Workshop 6 Practical aspects and clinical practice challenges when managing and optimising patients with chronic hypoparathyroidism <i>Professor Bart Clarke, USA and Associate Professor Kalliopi Kotsa, Greece</i> Workshop 7 Monitoring hypoparathyroidism patients: Challenges in adhering to guidelines <i>Professor Neil Gittoes, UK and Dr Peter Kamenicky, France</i>
11:15–11:30	Coffee break

This event is only open to healthcare professionals who register to attend. This meeting is initiated and funded by Takeda Global Medical Affairs. Presenters are paid an honorarium by Takeda for their participation in and consultation to this programme.

Copyright © 2019 Takeda Pharmaceutical Company Limited. All rights reserved

3rd European Symposium in Hypoparathyroidism

A Takeda-sponsored standalone meeting

11:30–12:15	<p>Importance of guideline adherence for patient management: A roundtable discussion</p> <p><i>Suggested topics for discussion include:</i></p> <ul style="list-style-type: none">• <i>Does clinical practice follow current guidelines</i>• <i>What are the challenges associated with the translation of practical guidance into clinical practice?</i>• <i>What can we do as a community to aid practice guidance adherence in hypoPT</i> <p><i>Moderator: Professor Bill Fraser, UK</i></p> <p><i>Faculty panel:</i></p> <p><i>Professor Jens Bollerslev, Norway</i></p> <p><i>Professor Bart Clarke, USA</i></p> <p><i>Associate Professor Kalliopi Kotsa, Greece</i></p> <p><i>Professor Neil Gittoes, UK</i></p> <p><i>Dr Peter Kamenicky, France</i></p>
12:15–12:50	<p>Real-world data: How can we obtain new evidence to fill the knowledge gaps in hypoparathyroidism?</p> <p><i>(Closing keynote presentation)</i></p> <p><i>Professor Neil Gittoes, UK</i></p>
12:50–13:20	<p>Real-world evidence: Panel discussion and Q&A</p> <p><i>Moderator: Professor Bart Clarke</i></p> <p><i>Faculty panel:</i></p> <p><i>Professor Maria Luisa Brandi, Italy</i></p> <p><i>Professor Lars Rejnmark, Denmark</i></p> <p><i>Professor Neil Gittoes, UK</i></p> <p><i>Professor Bill Fraser, UK</i></p>
13:20–13:25	<p>Meeting close</p> <p><i>Meeting Co-Chairs: Professor Lars Rejnmark, Denmark and Professor John Bilezikian, USA</i></p>
13:25	<p>Lunch and departures</p>

This event is only open to healthcare professionals who register to attend. This meeting is initiated and funded by Takeda Global Medical Affairs. Presenters are paid an honorarium by Takeda for their participation in and consultation to this programme.

Copyright © 2019 Takeda Pharmaceutical Company Limited. All rights reserved